New studies by National Institute of Allergy and Infectious Diseases (NIAID) scientists and grantees are helping to fill in pieces of the AIDS vaccine research puzzle. In three separate reports published in the February 1999 issue of the journal Nature Medicine, researchers report new insights about the kind of immune responses needed to protect against HIV infection. In the same issue, another group presents important findings regarding the safety of live, attenuated HIV vaccines.
Role of Neutralizing Antibodies (Back to Top)
Defining the precise immune responses that a vaccine must induce to protect against infection with HIV will allow scientists to design tailor-made vaccines that elicit those responses. Two series of experiments by Malcolm A. Martin, chief of NIAID's Laboratory of Molecular Microbiology, provide important new information about the role that antibodies can play in defending against HIV.
In one study, Martin and coworkers showed that "neutralizing" antibodies against HIV can prevent infection in primates. As their name implies, neutralizing antibodies bind to the virus in a way that prevents it from infecting cells. Martin's team isolated high levels of very potent neutralizing antibodies from healthy but HIV-infected chimpanzees and transferred them to rhesus monkeys. The monkeys were then exposed to SHIV, a hybrid virus composed of a simian immunodeficiency virus (SIV) core surrounded by HIV envelope proteins. SHIV normally causes infection in primates. However, none of the monkeys that had been passively immunized with the neutralizing antibodies became infected with SHIV.
In a second study, conducted with scientists from the National Cancer Institute, Martin's team investigated whether neutralizing antibodies to HIV can accelerate the removal of HIV from the blood of monkeys. The scientists measured HIV clearance after infusing large quantities of the virus into three groups of monkeys: animals that had been persistently infected with SHIV for several years (and therefore made antibodies that recognized the HIV proteins), uninfected animals that had received the anti-HIV antibodies as in the first study, and animals that had never been infected with HIV or SHIV.
The researchers found that HIV rapidly disappeared from the blood in each group of animals. However, in monkeys with neutralizing antibodies to HIV, virus clearance occurred more than twice as fast as in animals lacking these antibodies.
Martin acknowledges that scientists do not yet know how to elicit neutralizing antibodies to HIV in humans, nor can they produce antibodies that will cross-react broadly with different strains of HIV. He also notes that an effective preventive vaccine against HIV may have to elicit multiple immune responses that can interfere with different steps in the HIV life cycle. Still, his demonstration that neutralizing antibodies can prevent HIV infection should be a boon to HIV vaccine research.
"If we can learn how to raise sufficient quantities of neutralizing antibodies to a broad range of HIV strains, we will have made an important step towards an effective HIV vaccine," Martin stated.
Broad-Based Immunity Essential in Mice (Back to Top)
A study by another NIAID group suggests that HIV vaccines must elicit responses in all three major immune cell subsetsantibody-producing B cells, CD4+ (helper) T cells, and CD8+ (killer) T cellsto be effective.
Kim J. Hasenkrug, of NIAID's Rocky Mountain Laboratories in Hamilton, MT, and colleague Ulf Dittmer immunized mice with a live, attenuated vaccine against Friend virus, a retrovirus that causes a fatal, immunosuppressive disease in mice. The vaccine they used is highly effective at preventing disease. To determine which immune responses confer protection, they transferred various combinations of all three major immune cell subsets from immunized mice to non-immunized mice, then exposed the mice to a pathogenic form of Friend virus.
The researchers found that mice that had received just one or two immune cell types became infected and developed disease. Only mice that received all three immune cell types were completely protected from infection with the virus.
"Each lymphocyte subset seems to have unique and necessary functions that act in concert to induce protection," Hasenkrug notes. "It remains possible that single or dual lymphocyte subsets might be protective if transferred in overwhelming numbers, but the efficacy of vaccination with live, attenuated Friend virus seems to be related to its ability to stimulate multiple arms of the immune system. The implication is that only broadly based HIV vaccines that are designed to elicit responses in all three types of immune cells will prove effective."
Live, Attenuated VaccinesHow Safe? (Back to Top)
Some scientists believe that a live, attenuated HIV vaccine, composed of virus rendered non-pathogenic by removal of one or more essential genes, could be the best way to stimulate broad-based immunity to HIV. Others, however, question whether concerns about the safety of using live, attenuated HIV vaccines can be adequately addressed. Given HIV's propensity to mutate, they fear that an attenuated strain of HIV could revert to a pathogenic form.
Researchers led by NIAID grantee Ruth Ruprecht of the Dana-Farber Cancer Institute in Boston, collaborating with scientists at the Yerkes Regional Primate Research Center in Atlanta, report that an experimental live, attenuated SIV vaccine can cause AIDS in infant and adult monkeys. The vaccine consisted of an SIV strain from which three different genetic elements, each involved in viral replication, had been removed.
"Our findings confirm that this triply deleted SIV candidate vaccine retains its ability to cause AIDS," says Ruprecht. "Given the genetic similarities between HIV and SIV, a live, attenuated virus vaccine based on attenuation of replicative capacity should not be considered as a candidate for a human AIDS vaccine." Rather, she adds, attenuation strategies should focus on identifying viral genes that control virulence.
NIAID is a component of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose, and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma, and allergies. NIH is an agency of the U.S. Department of Health and Human Services.
For more information: Malcolm A. Martin, Chief, Laboratory of Molecular Microbiology, NIAID, NIH, Building 4, Room 315, 4 Center Drive, MSC 0460, Bethesda, MD 20892-0460. Tel: 301-496-4012. Fax: 301-402-0226. Email firstname.lastname@example.org.